Lei Qi, Wang Dong, Liu Chunhui, Ji Zhigang, Yan Su
Department of Urology, Peking Union Medical College Hospital, Beijing, China.
Transl Androl Urol. 2021 Feb;10(2):860-868. doi: 10.21037/tau-20-1069.
Low-intensity extracorporeal shock wave therapy (Li-ESWT) is an effective therapy for erectile dysfunction (ED) but is not widely recognized and applied. This prospective nonrandomized study aimed to investigate the efficacy and safety of Li-ESWT.
After a 4-week washout period of past ED treatment, patients entered one of 2 active treatment groups, either 9-week Li-ESWT or 100 mg on-demand sildenafil. Patients were evaluated in the first- and third-month following initiation of treatment. The Li-ESWT protocol comprised 2 sessions per week for 3 weeks, which were repeated after a 3-week interval. Patients in the drug group took self-administered sildenafil at a dose of 100 mg before intercourse. The primary outcome was the effectiveness of Li-ESWT measured by the International Index of Erectile Function-5 (IIEF-5) scores. Other measurements included erection hardness score (EHS) and Self-Esteem And Relationship (SEAR).
A total of 78 participants completed the study (46 in the Li-ESWT group and 32 in the sildenafil group). Overall, 26.9% of the participants (21/78) included were psychogenic. In the third month, the outcome measured by IIEF-5 was 21.52 in the Li-ESWT group and 21.26 in the sildenafil group (P>0.05). Proportion of improvement defined by minimal clinically important difference (MCID) criteria was 52.2% in the Li-ESWT group and 59.4% in the sildenafil group (P>0.05). The EHS and SEAR improvement was similar in the 2 groups (P>0.05 at baseline and third month). Transient and mild adverse events were observed in both groups.
In our study, a similar treatment efficacy and safety was shown by the application of Li-ESWT as on demand sildenafil.
低强度体外冲击波疗法(Li-ESWT)是治疗勃起功能障碍(ED)的一种有效疗法,但尚未得到广泛认可和应用。这项前瞻性非随机研究旨在探讨Li-ESWT的疗效和安全性。
在过去的ED治疗经过4周的洗脱期后,患者进入两个积极治疗组之一,即接受为期9周的Li-ESWT治疗或按需服用100mg西地那非。在治疗开始后的第一个月和第三个月对患者进行评估。Li-ESWT方案包括每周2次,共3周,在间隔3周后重复。药物组患者在性交前自行服用100mg西地那非。主要结局是通过国际勃起功能指数-5(IIEF-5)评分来衡量Li-ESWT的有效性。其他测量指标包括勃起硬度评分(EHS)和自尊与关系(SEAR)。
共有78名参与者完成了研究(Li-ESWT组46名,西地那非组32名)。总体而言,纳入的参与者中有26.9%(21/78)为心因性。在第三个月,Li-ESWT组IIEF-5测量的结果为21.52,西地那非组为21.26(P>0.05)。根据最小临床重要差异(MCID)标准定义的改善比例在Li-ESWT组为52.2%,在西地那非组为59.4%(P>0.05)。两组的EHS和SEAR改善情况相似(基线和第三个月时P>0.05)。两组均观察到短暂且轻微的不良事件。
在我们的研究中,Li-ESWT的应用显示出与按需服用西地那非相似的治疗疗效和安全性。